• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从头设计蛋白质的计算方法及其在人类免疫缺陷病毒 1、嘌呤核苷磷酸化酶、泛素特异性蛋白酶 7 和组蛋白去甲基酶中的应用。

Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.

机构信息

Department of Chemical Engineering, Princeton University, Princeton, NJ 08544, USA.

出版信息

Curr Drug Targets. 2010 Mar;11(3):264-78. doi: 10.2174/138945010790711914.

DOI:10.2174/138945010790711914
PMID:20210752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2894634/
Abstract

This paper provides an overview of computational de novo protein design methods, highlighting recent advances and successes. Four protein systems are described that are important targets for drug design: human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases. Target areas for drug design for each protein are described, along with known inhibitors, focusing on peptidic inhibitors, but also describing some small-molecule inhibitors. Computational design methods that have been employed in elucidating these inhibitors for each protein are outlined, along with steps that can be taken in order to apply computational protein design to a system that has mainly used experimental methods to date.

摘要

本文概述了计算从头设计蛋白质的方法,重点介绍了最近的进展和成功。描述了四个对药物设计很重要的蛋白质系统:人类免疫缺陷病毒 1、嘌呤核苷磷酸化酶、泛素特异性蛋白酶 7 和组蛋白去甲基酶。描述了每个蛋白质的药物设计目标区域,以及已知的抑制剂,重点介绍了肽类抑制剂,但也描述了一些小分子抑制剂。概述了为每个蛋白质阐明这些抑制剂所采用的计算设计方法,以及为一个迄今为止主要使用实验方法的系统应用计算蛋白质设计可以采取的步骤。

相似文献

1
Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.从头设计蛋白质的计算方法及其在人类免疫缺陷病毒 1、嘌呤核苷磷酸化酶、泛素特异性蛋白酶 7 和组蛋白去甲基酶中的应用。
Curr Drug Targets. 2010 Mar;11(3):264-78. doi: 10.2174/138945010790711914.
2
Structural analyses reveal two distinct families of nucleoside phosphorylases.结构分析揭示了核苷磷酸化酶的两个不同家族。
Biochem J. 2002 Jan 1;361(Pt 1):1-25. doi: 10.1042/0264-6021:3610001.
3
Drugs by design.设计药物。
Sci Am. 1993 Dec;269(6):92-8. doi: 10.1038/scientificamerican1293-92.
4
Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors.晶体学和建模方法在嘌呤核苷磷酸化酶抑制剂设计中的应用。
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11540-4. doi: 10.1073/pnas.88.24.11540.
5
Application of X-ray crystallographic methods in the design of purine nucleoside phosphorylase inhibitors.X射线晶体学方法在嘌呤核苷磷酸化酶抑制剂设计中的应用。
Ann N Y Acad Sci. 1993 Jun 23;685:237-47. doi: 10.1111/j.1749-6632.1993.tb35871.x.
6
Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines.基于结构的嘌呤核苷磷酸化酶抑制剂设计。5. 9-脱氮次黄嘌呤。
J Med Chem. 1994 Jul 22;37(15):2477-80. doi: 10.1021/jm00041a027.
7
Identification of a novel putative inhibitor of the Plasmodium falciparum purine nucleoside phosphorylase: exploring the purine salvage pathway to design new antimalarial drugs.鉴定新型疟原虫嘌呤核苷磷酸化酶的假定抑制剂:探索嘌呤补救途径以设计新型抗疟药物。
Mol Divers. 2017 Aug;21(3):677-695. doi: 10.1007/s11030-017-9745-8. Epub 2017 May 18.
8
Structure-based drug design: inhibitors of purine nucleoside phosphorylase. Index: structure-based drug design: inhibitors of PNP.基于结构的药物设计:嘌呤核苷磷酸化酶抑制剂。索引:基于结构的药物设计:PNP抑制剂。
Drug Des Discov. 1994 Jun;11(4):289-305.
9
Purine nucleoside phosphorylase: a target for drug design.嘌呤核苷磷酸化酶:药物设计的一个靶点。
Med Res Rev. 1993 May;13(3):209-28. doi: 10.1002/med.2610130302.
10
Determining the structural basis for specificity of ligands using crystallographic screening.利用晶体学筛选确定配体特异性的结构基础。
Cell Biochem Biophys. 2006;44(3):405-11. doi: 10.1385/CBB:44:3:405.

引用本文的文献

1
Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides.蛙类抗 SARS-CoV-2:蛙类皮肤肽潜在抗病毒作用的综述。
Virus Res. 2022 Jul 2;315:198769. doi: 10.1016/j.virusres.2022.198769. Epub 2022 Apr 14.
2
Bioprospecting of microbial enzymes: current trends in industry and healthcare.微生物酶的生物勘探:行业和医疗保健的当前趋势。
Appl Microbiol Biotechnol. 2022 Mar;106(5-6):1813-1835. doi: 10.1007/s00253-022-11859-5. Epub 2022 Mar 7.
3
Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides.对 MDM2/MDMX 靶向线性和大环肽的严格计算和实验研究。
Molecules. 2019 Dec 14;24(24):4586. doi: 10.3390/molecules24244586.
4
Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.定向进化蛋白质生物催化剂的合成生物学:智能导航序列空间。
Chem Soc Rev. 2015 Mar 7;44(5):1172-239. doi: 10.1039/c4cs00351a.
5
New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics.含有N端延伸和非天然氨基酸的新型补体抑制素肽具有强大的补体抑制作用和改善的溶解性特征。
J Med Chem. 2015 Jan 22;58(2):814-26. doi: 10.1021/jm501345y. Epub 2014 Dec 29.
6
Forcefield_NCAA: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family.力场_NCAA:从头算电荷参数,有助于发现和设计含有非天然氨基酸的治疗性蛋白质和肽,并将其应用于补体抑制素家族的互补抑制剂。
ACS Synth Biol. 2014 Dec 19;3(12):855-69. doi: 10.1021/sb400168u. Epub 2014 Jan 14.
7
Free energies for coarse-grained proteins by integrating multibody statistical contact potentials with entropies from elastic network models.通过将多体统计接触势与弹性网络模型的熵相结合来计算粗粒度蛋白质的自由能。
J Struct Funct Genomics. 2011 Jul;12(2):137-47. doi: 10.1007/s10969-011-9113-3. Epub 2011 Jun 15.
8
Multibody coarse-grained potentials for native structure recognition and quality assessment of protein models.用于天然结构识别和蛋白质模型质量评估的多体粗粒度势。
Proteins. 2011 Jun;79(6):1923-9. doi: 10.1002/prot.23015. Epub 2011 Apr 19.

本文引用的文献

1
The dead-end elimination theorem and its use in protein side-chain positioning.无环淘汰定理及其在蛋白质侧链定位中的应用。
Nature. 1992 Apr 9;356(6369):539-42. doi: 10.1038/356539a0.
2
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.通过新的从头蛋白质设计框架发现 HIV-1 的进入抑制剂。
Biophys J. 2010 Nov 17;99(10):3445-53. doi: 10.1016/j.bpj.2010.09.050.
3
New compstatin variants through two de novo protein design frameworks.通过两种从头蛋白质设计框架得到新型 Compstatin 变体。
Biophys J. 2010 May 19;98(10):2337-46. doi: 10.1016/j.bpj.2010.01.057.
4
Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure.通过结合进化序列保守性和 3D 结构预测蛋白质配体结合位点。
PLoS Comput Biol. 2009 Dec;5(12):e1000585. doi: 10.1371/journal.pcbi.1000585. Epub 2009 Dec 4.
5
Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells.小分子 USP7/HAUSP 泛素蛋白酶抑制剂稳定和激活细胞中的 p53。
Mol Cancer Ther. 2009 Aug;8(8):2286-95. doi: 10.1158/1535-7163.MCT-09-0097. Epub 2009 Aug 11.
6
Protein design by sampling an undirected graphical model of residue constraints.通过对残基约束的无向图形模型进行采样来进行蛋白质设计。
IEEE/ACM Trans Comput Biol Bioinform. 2009 Jul-Sep;6(3):506-16. doi: 10.1109/TCBB.2008.124.
7
Backbone and sidechain 1H, 13C and 15N resonance assignments of the Bright/ARID domain from the human JARID1C (SMCX) protein.人JARID1C(SMCX)蛋白中Bright/ARID结构域的主链和侧链1H、13C和15N共振归属
Biomol NMR Assign. 2008 Jun;2(1):9-11. doi: 10.1007/s12104-007-9071-7. Epub 2007 Dec 8.
8
Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger.由染色质结合的PHD指结构域失调引起的造血系统恶性肿瘤。
Nature. 2009 Jun 11;459(7248):847-51. doi: 10.1038/nature08036.
9
Direct binding of CoREST1 to SUMO-2/3 contributes to gene-specific repression by the LSD1/CoREST1/HDAC complex.CoREST1与SUMO-2/3的直接结合有助于LSD1/CoREST1/HDAC复合物对基因特异性的抑制作用。
Mol Cell. 2009 Apr 24;34(2):145-54. doi: 10.1016/j.molcel.2009.03.013.
10
Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.盐酸福罗司他丁(一种人嘌呤核苷磷酸化酶抑制剂)类似物的合成 - 第二部分。
Bioorg Med Chem Lett. 2009 May 15;19(10):2627-9. doi: 10.1016/j.bmcl.2009.04.018. Epub 2009 Apr 9.